Anumana earns first full FDA clearance for AI to detect low ejection fraction
Related Articles
Anumana Joins Accelerating Medicines Partnership Heart Failure Program to Advance ECG-AI® Research
Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditionsOctober 24, 2024
Anumana wins FDA clearance for ECG-AI algorithm
Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.October 03, 2023
StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week
Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation…April 20, 2021
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…June 21, 2023